Raptor Pharma Offers Update on PROCYSBI NDA Review

Raptor Pharmaceutical Corp. (Nasdaq: RPTP ), today announced that the U.S. Food and Drug Administration ("FDA") will require additional time to complete its review of the New Drug Application ("NDA") for RP103 (PROCYSBI™), for the potential treatment of nephropathic cystinosis. In a notice received today from the FDA, the initial Prescription Drug User Fee